AIM ImmunoTech Statistics
Share Statistics
AIM ImmunoTech has 63.78M shares outstanding. The number of shares has increased by 16.98% in one year.
| Shares Outstanding | 63.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 57.97M |
| Failed to Deliver (FTD) Shares | 34.86K |
| FTD / Avg. Volume | 7.54% |
Short Selling Information
The latest short interest is 491.37K, so 0.77% of the outstanding shares have been sold short.
| Short Interest | 491.37K |
| Short % of Shares Out | 0.77% |
| Short % of Float | 0.84% |
| Short Ratio (days to cover) | 1.63 |
Valuation Ratios
The PE ratio is -0.74 and the forward PE ratio is -0.59.
| PE Ratio | -0.74 |
| Forward PE | -0.59 |
| PS Ratio | 105.81 |
| Forward PS | 7.8 |
| PB Ratio | 2.09 |
| P/FCF Ratio | -0.98 |
| PEG Ratio | n/a |
Enterprise Valuation
AIM ImmunoTech Inc. has an Enterprise Value (EV) of 16.65M.
| EV / Earnings | -0.57 |
| EV / Sales | 82.43 |
| EV / EBITDA | -0.53 |
| EV / EBIT | -0.52 |
| EV / FCF | -0.76 |
Financial Position
The company has a current ratio of 1.68, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.68 |
| Quick Ratio | 1.72 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.13 |
| Cash Flow / Debt | -95.37 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -2.83% and return on capital (ROIC) is -291.42%.
| Return on Equity (ROE) | -2.83% |
| Return on Assets (ROA) | -1.49% |
| Return on Capital (ROIC) | -291.42% |
| Revenue Per Employee | 7.77K |
| Profits Per Employee | -1.11M |
| Employee Count | 26 |
| Asset Turnover | 0.01 |
| Inventory Turnover | -0.14 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -53.51% in the last 52 weeks. The beta is -0.36, so AIM ImmunoTech 's price volatility has been lower than the market average.
| Beta | -0.36 |
| 52-Week Price Change | -53.51% |
| 50-Day Moving Average | 0.24 |
| 200-Day Moving Average | 0.34 |
| Relative Strength Index (RSI) | 47.84 |
| Average Volume (20 Days) | 462.30K |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of $202.00K and earned -$28.96M in profits. Earnings per share was $-0.6.
| Revenue | 202.00K |
| Gross Profit | 160.00K |
| Operating Income | -31.92M |
| Net Income | -28.96M |
| EBITDA | -31.68M |
| EBIT | -31.92M |
| Earnings Per Share (EPS) | -0.6 |
Balance Sheet
The company has $5.44M in cash and $718.00K in debt, giving a net cash position of $4.72M.
| Cash & Cash Equivalents | 5.44M |
| Total Debt | 718.00K |
| Net Cash | 4.72M |
| Retained Earnings | -409.51M |
| Total Assets | 13.59M |
| Working Capital | -2.53M |
Cash Flow
In the last 12 months, operating cash flow was -$21.27M and capital expenditures -$585.00K, giving a free cash flow of -$21.85M.
| Operating Cash Flow | -21.27M |
| Capital Expenditures | -585.00K |
| Free Cash Flow | -21.85M |
| FCF Per Share | -0.45 |
Margins
Gross margin is 79.21%, with operating and profit margins of -15.80K% and -14.34K%.
| Gross Margin | 79.21% |
| Operating Margin | -15.80K% |
| Pretax Margin | -14.34K% |
| Profit Margin | -14.34K% |
| EBITDA Margin | -15.68K% |
| EBIT Margin | -15.80K% |
| FCF Margin | -10.82K% |
Dividends & Yields
AIM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -272.73% |
| FCF Yield | -157.31% |
Analyst Forecast
The average price target for AIM is $2.75, which is 1150% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.75 |
| Price Target Difference | 1150% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jun 11, 2019. It was a backward split with a ratio of 1:44.
| Last Split Date | Jun 11, 2019 |
| Split Type | backward |
| Split Ratio | 1:44 |
Scores
| Altman Z-Score | -48.84 |
| Piotroski F-Score | 3 |